Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341567 | 0.87 | ALDH1A1 (0.42) | LMNAOPRM1ALDH1A1TDP1CYP3A4 | |
| SCHEMBL11526148 | 0.87 | TSHR (0.36) | ALDH1A1TSHR | |
| SCHEMBL28167341 | 0.84 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL6011981 | 0.84 | LMNA (0.46) | LMNAOPRM1ALDH1A1TDP1CYP3A4 | |
| SCHEMBL18222610 | 0.84 | LMNA (0.41) | LMNAOPRM1ALDH1A1TDP1TSHR | |
| SCHEMBL18222609 | 0.84 | LMNA (0.41) | LMNAOPRM1ALDH1A1TDP1TSHR | |
| SCHEMBL5683598 | 0.82 | LMNA (0.54) | LMNAOPRM1TSHR | |
| SCHEMBL29640413 | 0.82 | LMNA (0.54) | LMNAOPRM1TSHR | |
| SCHEMBL5594937 | 0.82 | LMNA (0.43) | LMNAOPRM1ALDH1A1TDP1CYP3A4 | |
| SCHEMBL20821296 | 0.82 | LMNA (0.54) | LMNAOPRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | LMNA 1943/4885OPRM1 4583/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.